Trial Profile

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS-209 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nouscom

Most Recent Events

12 Oct 2025 Results presented in the Nouscom media release
12 Oct 2025 According to a Nouscom media release, data from the trial will be presented in a poster session at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting 2025.
09 Jul 2025 Planned End Date changed from 30 Nov 2026 to 30 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com